The binding of low-density lipoproteins (LDL) as well as LDL modified by cyclohexanedione (CHD-LDL) to gel-filtered platelets (GFP) and its effect on platelet function were studied in normal and in homozygous familial hypercholesterolaemic (HFH) subjects. Only normal-derived LDL could significantly compete with normal 125I-labelled LDL for binding to normal platelets. When GFP from normal subjects were incubated with normal LDL at concentrations of 25-200kg of protein/ml, platelet aggregation in the presence of thrombin (0.5i.u./ml) was increased by 65-186%. CHD-LDL, at similar concentrations, caused the opposite effect and decreased platelet aggregation by 26-47%. Both LDL and CHD-LDL (100ig/ml) from HFH patients, when incubated with normal GFP, caused a significant reduction in platelet aggregation (33 and 50% respectively). When HFH-derived platelets were used, both patient LDL and CHD-LDL (but not the normal lipoprotein) could markedly compete with the patient 125I-labelled LDL for binding to the platelets. LDL and CHD-LDL (100yg/ml) from normal subjects decreased aggregation of HFH-platelets by 52 and 85% respectively, while corresponding concentrations of LDL derived from HFH subjects (HFH-LDL) and CHD-LDL derived from HFH subjects (CHD-HFH-LDL) increased platelet aggregation by 165 and 65% respectively. The present results support the following conclusions: (1) platelet activation by LDL in normal subjects is through the arginine-rich apoprotein-binding site; (2) more than one binding site for LDL exists on platelets; (3) under certain circumstances, LDL binding can cause a reduction in platelet activity; (4) specificity for LDL binding to the platelets resides in different regions of the lipoprotein in HFH and in normal subjects. We have thus suggested a model for LDL-platelet interaction in normal and in HFH subjects.
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Hypercholesterolaemia and blood platelet function are interrelated and play a major role in atherosclerosis (Mustard & Packham, 1975; Ross & Glomset, 1976) . The effect of plasma lowdensity lipoproteins (LDL) on platelet function has been provided by studies in vitro and investigations of patients with familial hypercholesterolaemia (FH) . Patients excessive amounts of LDL due to a partial (heterozygous) or complete (homozygous) absence of LDL receptors in various cell cultures (Goldstein et al., 1983) , have been shown to have platelet hyperactivity, both in vitro (Carvalho et al., 1974; Colman, 1978; Aviram & Brook, 1982) and in vivo (Joist et al., 1974; Zahavi et al., 1982) . Recently it has been shown that platelet hyperactivity in these patients is mediated through the presence of some factors present in FH patients' plasma (Aviram & Brook, 1982) and that at least one of these factors might be LDL (Viener et al., 1984) . We and others Koller et al., 1982) well as platelet function (Aviram & Brook, 1981a , 1983a ,b,c, 1984 . The binding to normal platelets seems to be dependent on the presence of a number of functionally significant, positively charged arginine or lysine residues on the lipoprotein surface . When normal LDL is subjected to a specific chemical modification with cyclohexane-1,2-dione, receptor-lipoprotein interactions are abolished (Mahley et al., 1977; Aviram et al., 1981) . In contrast with HFH fibroblasts, which apparently exhibit no specific LDL binding (Goldstein et al., 1983) , HFH platelets exhibit specific accumulation of LDL (Aviram & Brook, 198 lb) . Differences in the lipoprotein composition between normal and FH subjects have been described Viener et al., 1984) , and the platelet composition has been shown to be abnormal in these patients (Shastri et al., 1980; Nordoy & Rodest, 1971) .
Although results of experiments in vitro support the conclusion that some platelet functions are affected by the lipid content of their environment (Shattil et al., 1975) , it has not been proven that this effect is through the receptors mentioned above. The goal of the present study was to examine two interrelated and important lines of investigation, the first dealing with significance of the LDL binding sites and the latter dealing with the differences between normal-and HFH-derived platelet LDL binding sites.
Materials and methods

Subjects
Healthy normal volunteers included five female and 17 male subjects, whose ages ranged from 23 to 55 years (mean 29 years); they were on no medications and had normal plasma lipid concentrations [plasma cholesterol, 4.8+0.7mmol/l (mean + S.D.); plasma triacylglycerols, 1.13 + 0.23 mmol/l].
The patients, two males and one female, aged 20, 15 and 25 years respectively, were homozygous for the familial form of type II hyperlipoproteinaemia, determined by plasma lipid concentrations, lipoprotein electrophoresis and quantification (Hatch & Lees, 1968) as well as family history. These patients had plasma cholesterol levels of 13.62, 14.39 and 15.65mmol/l and triglyceride levels of 0.90, 1.04 and 1.11 mmol/l. All had marked hypercholesterolaemia; tendon, planar and tuberous xanthomata and, in at least two patients, premature atherosclerosis. They were treated by plasma exchange on an outpatient basis at 3-4-weekly intervals. None of the subjects had taken any medication for at least 2 weeks preceding the experiments. Informed consent for the study was obtained from each subject.
On each analysis when comparing patients with controls, age-matched pairs were studied. Venous blood was collected, after a 14h fast, through silicone-treated needles into plastic syringes. The blood was added to plastic tubes containing disodium EDTA (1 mmol/l final concn.) for lipoprotein separation. For platelet prepation, 9 vol. of blood were added to 1 vol. of 3.8% (w/v) sodium citrate.
Preparation of lipoproteins
Plasma lipoproteins were separated by discontinuous-density-gradient ultracentrifugation (Aviram, 1983) . The density of 4ml samples of plasma was raised to 1.25kg/l with KBr. A 4ml portion of a density solution of 1.04kg/l was then carefully laid over the plasma sample, followed by 4ml of NaCl (p = 1.006kg/l). Ultracentrifugation was performed in an SW-41 rotor in a Beckman L2-65B preparative ultracentrifuge for 48 h at 4°C and 35000rev./min. LDL was then carefully removed and dialysed extensively against NaCl (150mmol/l), pH8.6. The purity of the LDL fraction was analysed by cellulose acetate electrophoresis, Ouchterlony double immunodiffusion and immunoelectrophoresis for all the experiments. The lipoproteins were pure and free ofother plasma proteins. Lipoprotein protein concentration was determined by the procedure of Lowry et al. (1951) , with bovine serum albumin as standard. The cholesterol and triglycerol content of each lipoprotein was determined by enzymic methods on a centrifugal fast analyser (Gemsaec, Fairfield, NJ, U.S.A.).
Part of the LDL prepared as above was chemically modified by cyclohexanedione (Mahley et al., 1977) . A 1 ml portion of LDL (Smg/ml) was added to 2ml of cyclohexane-1,2-dione (0.15mmol/l) in sodium borate (0.2mmol/1), pH 8.1, and incubated for 2h at 35°C. The CHDmodified LDL (CHD-LDL) was dialysed against NaCl solution (p = 1.006kg/l) with EDTA (1 mmol/l), pH 8.6, and filtered through a 0.22pm-pore-size Millipore filter before use.
CHD-modified albumin was prepared in a manner similar to that used for CHD-LDL, albumin (5mg/ml) being used instead of LDL. LDL accumulation by platelets Gel-filtered platelets (100000/dl) were incubated with 125I-labelled LDL (25 g of protein/ml; 175-215c.p.m./mg of protein) for 30min at 37°C with increasing concentrations of LDL or CHD-LDL. Platelet samples were washed with 5ml of Hepes buffer [Hepes (5 mmol/l), NaCl (137mmol/1), MgCl2 (1.2mmol/1), NaHCO3 (12mmol/1), NaH2PO4,H2O (0.4mmol/1), KCl (2.7mmol/1) and glucose (0.6mmol/1), pH 7.4] four times, and the resuspended pellet (O.5 ml) was overlayered on 1.Oml of foetal-calf serum and spun down for 5min at 8000g in an Eppendorf 3200 minicentrifuge. The supernatant was removed, and the pellet was then counted for a radioactivity in a scintillation counter. Platelet preparation Platelet-rich plasma was prepared from citrated whole blood by low-speed centrifugation for 1Omin at 23°C and 200g. GFP were isolated by chromatography of 5ml of platelet-rich plasma on a Bio-Gel A 50-M (50-100 mesh; BioRad Laboratories) column (27 mm x 90mm) preequilibrated with Hepes buffer, pH7.4. Fractions (1 ml) were collected during elution with the buffer at a flow rate of 1 ml/min, and 60% of the platelets were recovered in the GFP pool that was collected as a visible, turbid peak. (Born, 1969 (New England Nuclear; NEC-225) for 30min at 37°C and then centrifuged at 1700g for 10min at room temperature. The platelet pellet was then resuspended in an equivalent volume of Hepes buffer and incubated with the lipoprotein. At the end of the incubation, 450g1 samples were prepared, and either saline or thrombin (0.5i.u./ml) was added (50l) and incubated for 10min at 37°C with constant stirring. A 400Mu portion of EDTA (l00mmol/l) was then added in order to prevent re-uptake of [14C]-serotonin.
A sample was taken for total-radioactivity counting, and the remaining platelet suspension was centrifuged for 10min at 4°C and 8000g. Portions of the supernatant of both samples were counted for radioactivity in a liquid-scintillation counter, with toluene/Triton X-100 as a scintillation fluid. Platelet [14C]serotonin release was calculated as a percentage of the radioactivity released by thrombin.
Statistics
Statistical analysis of the data was performed in all cases by the Wilcoxon rank test. All the results, unless otherwise noted, are expressed as the means+s.E.M., and each experiment was repeated three times.
Results
The cell surface of normal GFP was shown to have 1500 binding sites for normal 125I-LDL (Aviram & Brook, 1983a; Aviram et al., 1981; Koller et al., 1982) . The degree of binding of normal 125I-LDL to normal platelets was 30-40% lower (Aviram & Brook, 1981b) .
When normal GFP were incubated with normal '25I-labelled LDL, normal-derived LDL (but not CHD-LDL) at 1 mg of protein/ml reduced platelet accumulation of the iodinated LDL by 80%. Both LDL and CHD-LDL, when derived from patients with HFH, could only minimally compete with 125I-labelled LDL for accumulation by the normal platelets (Fig. 1) . When similar experiments were done using platelets derived from HFH patients, the patient LDL as well as its CHD-LDL reduced the patient 125I-labelled LDL binding by 80%. However, normal LDL or CHD-LDL reduced the platelet accumulation of the patient '251-labelled LDL by only 5%. Fig. 2 (Fig. 3a) , not we examined, no trend in platelet activity could be seen; this, too, is in contrast with what was seen when normal LDL was used.
CHD-LDL derived from HFH patients caused effects similar to those seen with CHD-LDL derived from normal subjects (Fig. 3a) . Platelet aggregation decreased, in comparison with the control containing GFP alone, by 57, 60, 50 and 44% at CHD-LDL-HFH concentrations of 25, 50, 100 and 200ig of protein/ml respectively. This effect was greater than that caused by CHD-LDL obtained from normal subjects.
Platelets obtained from HFH patients were affected by LDL and CHD-LDL in a different manner (Fig. 3b) . LDL from these patients caused a significant increase in platelet-aggregation velocity, whereas LDL from normal subjects caused a significant decrease. Lipoprotein concentrations of 25, 50, 100 and 200pg of protein/ml caused a decrease of 50, 66, 52 and 35% respectively, when normal LDL was used, but caused an increase of 205, 170, 165 and 180%, respectively when LDL derived from HFH patients was added to HFH-GFP.
After incubating platelets derived from HFH patients with CHD-LDL obtained from normal individuals, a diminution in the aggregation response was observed compared with the control containing no lipoprotein in the medium (Fig. 3b ). An increment in the aggregation response was observed when CHD-LDL from HFH patients was incubated with these platelets. Lipoprotein concentrations of 25, 50, 100 and 200pg of protein/ml caused an increment of 115, 155, 65 and 140% respectively when CHD-LDL derived from HFH patients was added, but when the lipoprotein was CHD-LDL obtained from normal subjects, the results showed a decline in platelet aggregation by 63, 55, 85 and 42% respectively.
Discussion
The LDL high-affinity binding sites on platelets and on other cell surfaces in normal subjects are specific for arginine-rich residues of the apoprotein moiety (Mahley et al., 1977; Aviram et al., 1981) . It was assumed that, if the LDL-platelet interaction is through these high-affinity binding sites, then by using cyclohexanedione-modified LDL, unable to bind through the arginine residues, the lipoprotein would lose its effect on the platelets. Surprisingly, the results in this study show not only that CHD-LDL had an effect on platelets, but that, in contrast with LDL, it caused a decline in platelet activity. This effect of CHD-LDL (Fig. 2) and the previous observation (Mahley et al., 1977) , that CHD itself can cause a decrease in receptor binding, made it pertinent to prove that the results
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shown for CHD-LDL were not actually the effect of CHD alone. By using cyclohexanedionemodified albumin, prepared in a manner and at concentrations similar to those used with CHD-LDL, it was shown that CHD had a minor desensitizing effect (up to 10%), if at all, on platelet activity at the concentrations used in our study. Competitive inhibition of labelled LDL (derived from normal subjects) binding to normal platelets (Fig. 1) showed that LDL high-affinity binding sites were specific for the arginine residues of LDL derived from normal subjects. In HFH patients, Fig. 1 shows that the binding sites were specific for LDL derived from these patients, but probably not to the arginine residues.
The addition of lipoproteins to GFP did not give rise to aggregation, but affected the aggregation response to thrombin. Shattil et al. (1975) showed that the enrichment of platelet plasma membranes with cholesterol increased platelet sensitivity. Transfer of phospholipids between platelets and lipoproteins has been demonstrated (Bereziet et al., 1978) and shown to be a process short enough to be completed in the time lipoproteins were incubated with platelets in the present study. The cholesterol content of the platelet plasma membrane is directly correlated with the plasma cholesterol level (Shattil et al., 1975) , and it has recently been shown that the LDL cholesterol/protein ratio, which has a significant effect on platelet activity (Viener et al., 1984) , differs in HFH and in normal subjects (Jadhav & Thompson, 1979) . A possible role of the LDL binding sites may be the transfer of lipids between LDL and the platelet plasma membrane, causing a change in the physicochemical properties of the membrane, with consequent sensitization of the platelets to aggregating agents (Shattil et al., 1975) .
No strict correlation has been proved between LDL binding and its effect on platelet activity. The complete displacement of bound labelled LDL is at a dose much higher (Fig. 1) than that needed for maximum effect on platelet aggregation (Figs. 2  and 3 ). Furthermore, as mentioned above, the effect of LDL might be through the transfer of lipid and not related to the apoprotein bound to the cell surface, making it even less likely that the doseresponse relation is identical with the extent of LDL binding. Nevertheless, our study suggests the existence of two unrelated binding sites differing in their affinity for LDL. This is due to our observation (Fig. 2) ing that, at higher concentrations, saturation of the high-affinity binding sites had occurred and that the decrease in platelet activity was due to the effect of the other binding sites that cause platelet inhibition. In HFH patients (Fig. 3a) , CHD modification had only a minor effect on platelet-LDL interaction, and the effect of the lipoprotein did not decrease with increasing concentrations of the lipoprotein. We therefore conclude that at least two binding sites exist on human platelets, that the high-affinity binding sites differ between normal and HFH subjects, and that the high-affinity binding sites on the cell surface of the latter probably reach a maximal effect at higher concentrations of LDL than in normal subjects.
Low-affinity binding sites have been shown to exist on fibroblast cells and are significant only at relatively high LDL concentrations (Steinberg, 1978) . On platelets, these binding sites, we propose, act similarly to, or are identical with, those of HDL and possibly function as an acceptor of cholesterol from the plasma membrane (Weinstein et al., 1976) . In a recent report, Aviram & Brook (1983a) showed in normal platelets that labelled LDL uptake by platelets is only minimally affected by unlabelled HDL, whereas the accumulation of a similar concentration of labelled HDL was significantly inhibited by unlabelled LDL. This observation can be explained by competitive inhibition between HDL and LDL on the low-affinity binding sites. Therefore, unlabelled HDL would have only a minor effect on labelled LDL accumulation, due to LDL's ability to bind to highaffinity sites. On the other, hand, unlabelled LDL would have a marked effect on labelled HDL binding (to low-affinity binding sites).
The results of cross experiments using lipoproteins, from HFH patients or from normal subjects, to platelets derived from normal (Fig. 3a) or HFH (Fig. 3b) Fig. 4 . It seems reasonable to assume that the effect of the high-affinity binding site is dominant and that only at relatively high concentrations does the low-affinity binding site have any significant effect; therefore, when a lipoprotein can bind to both sites, the net effect will be an increase in platelet activity (Fig. 4) , at least at relatively low lipoprotein concentrations. CHD-LDL derived from normal subjects probably interacts only through the low-affinity binding sites of (-'--) represents the specific 'activating' binding site for LDL of HFH platelets. This binding site differs from that of normal platelets, and therefore CHD has no effect on LDL binding in HFH subjects. The low-affinity binding site is identical in HFH and normal subjects. LDL derived from normal subjects cannot interact with the specific binding site; therefore both LDL and CHD-LDL from normal subjects, which interact only through the lowaffinity binding sites, inhibit platelet aggregation.
normal-or HFH-derived platelets, causing a decrease in their activity. On the other hand, CHD-LDL derived from HFH patients could interact through the high-affinity binding sites of HFH-derived platelets, causing an increase in their activity in the presence of thrombin. In a recent report (Viener et al., 1984) , it was shown that incubating normal platelets with FH-derived LDL increased platelet activity to a greater extent than when normal-derived LDL was used. It is possible that, in these patients (not like in HFH patients), their abnormal LDL composition results in a preferred activation of the high-affinity binding sites over that caused by normal lipoprotein. The different effect of LDL derived from normal or HFH subjects on platelet function is probably related to differences in LDL composition. Such a difference has been observed, but has not been shown to be in the apoprotein moiety, believed to be the key to cell-recognition sites (Knight & Soutar, 1982) . It is likely that, although cell recognition is through the apoprotein moiety, it is the lipid composition that influences platelet activation. Although it has been reported that fibroblasts derived from normal subjects do not differentiate in LDL degradation between those derived from normal or HFH patients (Goldstein et al., 1983) , Knight & Soutar (1982) have reported that CHD modification inhibits normal LDL binding to fibroblasts to a greater extent that HFH-derived LDL binding. This is in agreement with our observations that only in normal subjects do the arginine residues play an important part in LDL binding. CHD modification of HFH-derived LDL, but not of normal LDL, increased its degradation by macrophages (Knight & Soutar, 1982) , and this too suggests that LDL differs in HFH patients, in comparison with LDL derived from normal subjects, with regard to cell recognition.
Our study thus demonstrates the significance of the LDL binding sites, since LDL binding is related to platelet activation by the lipoprotein.
Platelets from HFH subjects do possess LDL binding sites, but these sites are different qualitatively from those found in normal subjects. The altered patient platelet LDL binding sites might be responsible for platelet hyperactivity in these patients.
